Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moxonidine: some controversy.

S A Doggrell1

  • 1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand.

Expert Opinion on Pharmacotherapy
|May 5, 2001
PubMed
Summary
This summary is machine-generated.

Moxonidine effectively lowers blood pressure by acting on imidazoline I(1) receptors and alpha-2 adrenoceptors. While safe for hypertension, it is contraindicated in heart failure due to safety concerns.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do interventions by allied health professionals discussing adherence to insulin improve this adherence?

Diabetes research and clinical practice·2014
Same author

Does intervention by an allied health professional discussing adherence to medicines improve this adherence in Type 2 diabetes?

Diabetic medicine : a journal of the British Diabetic Association·2010
Same author

The heart as a target for oestrogens.

Heart, lung & circulation·2005
Same author

Clinical evidence for drug treatments in obesity-associated hypertensive patients--a discussion paper.

Methods and findings in experimental and clinical pharmacology·2005
Same author

Responsiveness, affinity constants and beta 2-adrenoceptor reserves for isoprenaline on portal veins from normo- and pre- and hypertensive rats.

Autonomic & autacoid pharmacology·2003
Same author

Pharmacology down under in 2000.

Drug news & perspectives·2003

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Moxonidine's antihypertensive mechanism was initially attributed to central alpha-2 adrenoceptors.
  • Emerging evidence suggests predominant action at imidazoline I(1) receptors in the rostral ventrolateral medulla.
  • The precise site and mechanism of action remain debated, potentially varying with administration route.

Purpose of the Study:

  • To review the mechanism of action, therapeutic effects, and safety profile of moxonidine.
  • To explore moxonidine's potential applications beyond hypertension.
  • To consolidate current understanding of moxonidine's clinical utility.

Main Methods:

  • Review of existing literature on moxonidine's pharmacology and clinical trials.

Related Experiment Videos

  • Analysis of animal model data for various conditions.
  • Examination of human pharmacokinetic and safety data.

    • Main Results:

    • Moxonidine demonstrates antihypertensive effects in humans and beneficial outcomes in animal models for conditions including diabetes, kidney disease, glaucoma, pain, and ethanol withdrawal.
    • Pharmacokinetics follow a one-compartment model with renal elimination being primary.
    • A clinical trial (MOXCON) in heart failure was halted due to increased mortality, contraindicating its use in this population.

    Conclusions:

    • Moxonidine is a safe and effective antihypertensive agent.
    • Contraindicated in heart failure patients.
    • Further development for other clinical indications is warranted, excluding heart failure.